Biocept Company

Biocept, an emerging biotechnology leader in cell separation technology, is developing a new, powerful class of diagnostic assays for personalized medicine in early detection, diagnosis and monitoring of cancer. The CEEâ„¢ Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate, less invasive diagnoses. Isolation, purification and analysis of rare cells are managed within their state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.
Technology: P4 Medicine
Industry: Biotechnology, Health Care, Health Diagnostics
Headquarters: San Diego, California, United States
Founded Date: 1993-01-01
Employees Number: 51-100
Funding Status: IPO
Investors Number: 3
Total Funding: $43.2M
Estimated Revenue: $1M to $10M
Last Funding Type: Post-IPO Equity

Visit Website
info@biocept.com
https://twitter.com/biocept
Register and Claim Ownership